AstraZeneca investors punish firm over reports of $400-billion Bristol Myers pharma deal
Get the Finance newsletter
Daily finance — markets, central banks, M&A, the prints that move money. Free.
- AstraZeneca shares closed down roughly 9 per cent on Monday — the steepest single-day drop since 2020 — on reports of merger talks with Bristol Myers Squibb, while Bristol Myers shares slipped less than 1 per cent in early trading.
- A confirmed combination would create the world's fourth-largest drugmaker by market value and largest by revenue, with the two firms carrying a combined market capitalization of nearly US$400-billion as of Friday (AZN at US$264-billion, BMS at US$133-billion).
- Lucy Coutts of AstraZeneca shareholder JM Finn said the only advantage for AZN would be accelerating its U.S. footprint, arguing 'BMS shareholders would be the winners of any combination with AZN.'
- Markus Manns of Union Investment called a merger 'the pharmaceutical industry's equivalent of the FIFA privatization moment,' saying it 'does not make strategic or financial sense' and would disrupt a well-run company with a full pipeline under Pascal Soriot's 14-year tenure.
- Since Trump's return to office, AstraZeneca has invested tens of billions in U.S. manufacturing and is targeting half of its US$80-billion 2030 revenue goal from the U.S. market; the company generated about US$59-billion in revenue last year.
- Shore Capital's Sean Conroy flagged potential antitrust scrutiny from overlap between Bristol Myers' Opdivo and AstraZeneca's Imfinzi — both cancer immunotherapies — while noting a deal could help AZN address a patent cliff it faces after 2030.
- Lukas Leu of ATG Healthcare conceded cost synergies and neuroscience reach were possible but warned 'mega-mergers kill innovation and agility, and would be growth-dilutive for AstraZeneca in the near term.'
Why it matters: AZN's 9 per cent slide — its worst since 2020 — against BMS's sub-1 per cent dip is a rare shareholder rebuke of Soriot's 14-year track record and signals investors believe the tie-up dilutes AstraZeneca's stronger pipeline and lower patent-cliff exposure. A deal would effectively make a British company absorb one of America's biggest pharma commercial footprints at a moment when AstraZeneca is already racing toward 50 per cent U.S. revenue by 2030.
